A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir Article

sustainable development goals

publication date

  • April 19, 2023

webpage

published in

keywords

  • HIV prevention
  • elvitegravir
  • microbicide agent
  • tenofovir alafenamide
  • vaginal insert

volume

  • 13